Clinical trial
Efficacy of Tegaserod in Relieving the Symptoms of Female Patients With…
NCT00142987 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00142987 |
|---|---|
| Title | Efficacy of Tegaserod in Relieving the Symptoms of Female Patients With Irritable Bowel Syndrome (IBS), Excluding Those With Predominant Diarrhea IBS |
| Official title | Efficacy of Tegaserod in Relieving the Symptoms of Female Patients With Irritable Bowel Syndrome (IBS), Excluding Those With Predominant Diarrhea IBS |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | IBS-C and IBS With Mixed Bowel Habits |
| Intervention type | Drug |
| Interventions | Tegaserod |
| Enrollment | 664 |
| Start date | Apr 1, 2004 |
| Completion | Jun 1, 2005 |
| First posted | Sep 2, 2005 |
| Last update posted | Jan 28, 2008 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: